《雷公藤多苷/雷公藤片治疗类风湿关节炎用药指南》编制说明  

Editorial explanation for Clinical practice guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in treatment of rheumatoid arthritis

作　　者：林娜[1] 姜泉[2] 刘维[3] 刘健[4] 黄清春[5] 吴宽裕[6] 涂胜豪[7] 周祖山 陈卫衡 李小霞[10] 张彦琼 李泰贤 LIN Na;JIANG Quan;LIU Wei;LIU Jian;HUANG Qing-chun;WU Kuan-yu;TU Sheng-hao;ZHOU Zu-shan;CHEN Wei-heng;LI Xiao-xia;ZHANG Yan-qiong;LI Tai-xian(Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China;Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300381,China;the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine,Hefei 230031,China;Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou 510020,China;the Second People's Hospital of Fujian University of Traditional Chinese Medicine,Fuzhou 350003,China;Tongji Hospital Affiliated to Tongji Medical School of Huazhong University of Science and Technology,Wuhan 430030,China;&Honghu Hospital of Traditional Chinese Medicine,Honghu 433200,China;the Third Affiliated Hospital of Beijing University of Chinese Medicine,Beijing 100029,China;Xuanwu Hospital,Capital Medical University,Beijing 100053,China)

机构地区：[1]中国中医科学院中药研究所,北京100700 [2]中国中医科学院广安门医院,北京100053 [3]天津中医药大学第一附属医院,天津300381 [4]安徽中医药大学第一附属医院,安徽合肥230031 [5]广东省中医院,广东广州510020 [6]福建中医药大学附属第二人民医院,福建福州350003 [7]华中科技大学同济医学院附属同济医院,湖北武汉430030 [8]&湖北省洪湖市中医院,湖北洪湖433200 [9]北京中医药大学第三附属医院,北京100029 [10]首都医科大学宣武医院,北京100053

出　　处：《中国中药杂志》2020年第17期4154-4157,共4页China Journal of Chinese Materia Medica

基　　金：国家自然科学基金面上项目(81974526,81974529,81974537,81873068);北京市自然科学基金项目(7192139);中央级公益性科研院所基本科研业务费专项(Z2017082,ZXKT19013)。

摘　　要：《雷公藤多苷/雷公藤片治疗类风湿关节炎用药指南》(编号T/CACM 1337-2020)已于2020年6月24日由中华中医药学会标准化办公室正式发布。为了帮助广大医务工作者更加准确地理解和应用该指南,该文将2018年1月立项以来,项目组按照中华中医药学会标准化办公室发布的"中成药临床应用专家共识的制订流程"对指南研制的整个过程以及相关技术环节进行总结和梳理,形成编制说明,以供指南使用者参考,也可为其他中成药临床应用指南的研制提供借鉴和帮助。Clinical practice guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the treatment of rheumatoid arthritis(T/CACM 1337-2020)was approved on June,2020 by the Standardization Office of Chinese Association of Chinese Medicine.Our group developed this guideline for the clinical application of Tripterygium Glycosides/Tripterygium wilfordii Tablets according to the manual for the clinical experts consensus of Chinese patent medicine from January,2018,when this project was approved by Chinese Association of Chinese Medicine.In this article,the detailed information on our compilation process was provided,in order to facilitate the understanding and the application of the guideline,as well as provide reference for the development of clinical practice guideline for other Chinese patent medicine.

关 键 词：雷公藤多苷片 雷公藤片 类风湿关节炎 临床用药指南 编制说明 

分 类 号：R259[医药卫生—中西医结合]